Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis PR NewswireNovo Nordisk’s Wegovy gets accelerated US approval for liver disease MASH ReutersNovo Nordisk announces FDA approves additional indication of Wegovy TipRanksNovo Nordisk’s Wegovy Gets US Approval for Liver Disease Bloomberg.comNovo Nordisk’s Wegovy Expands into the MASH Market: A Strategic Catalyst for Long-Term Growth AInvest